Drugs / INS1201
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06817382 | Jul 2025 → Jan 2028 expected | Duchenne muscular dystrophy | Insmed Gene Therapy LLC | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INS1201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06817382 ↗ |
| Route | Intrathecal | “single intrathecal injection” NCT06817382 ↗ |